ArticleChinese medicine2026
Berberine attenuates diabetic kidney injury via FOXO1/SP1-associated regulation of renal SGLT-2 expression.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundBerberine (BBR), a plant-derived isoquinoline alkaloid, has been reported to exert anti-hyperglycemic and renoprotective effects. However, the mechanism by which BBR regulates renal glucose transport under diabetic conditions remains unclear. Sodium-glucose cotransporter-2 (SGLT-2), mainly expressed in renal proximal tubular epithelial cells, plays a key role in renal glucose reabsorption. This study investigated whether BBR attenuates diabetic kidney injury by regulating SGLT-2 expression and examined the potential involvement of FOXO1 and SP1 in this regulation.
methodsDb/db mice and high-glucose-exposed human kidney-2 (HK-2) cells were used to evaluate the effects of BBR, empagliflozin (EM), and their combination. Metabolic and renal phenotypes were assessed by biochemical, histological, and ultrastructural analyses. Network pharmacology, public transcriptomic data mining, molecular docking, cellular thermal shift assay (CETSA), quantitative real-time PCR, western blotting, immunofluorescence, nuclear-cytoplasmic fractionation, co-immunoprecipitation, 2-NBDG uptake, dual-luciferase reporter assays, FOXO1 overexpression, and pharmacological interference with SP1-associated regulation were performed to investigate the regulatory mechanism.
resultsBoth BBR and EM improved metabolic abnormalities and renal injury in db/db mice, whereas combined treatment produced marked metabolic and renal improvements but was accompanied by an increasing trend in AST. BBR reduced hyperglycemia, improved glucose tolerance and enhanced the glucose-lowering response to exogenous insulin during the ITT, suppressed urinary albumin excretion, and alleviated renal histopathological and ultrastructural damage. Molecular docking and qualitative CETSA findings suggested that FOXO1 may represent a potential molecular target of BBR. In HK-2 cells, high-glucose stimulation increased SGLT-2 expression and glucose uptake, accompanied by dysregulation of FOXO1 and SP1 signaling. BBR downregulated FOXO1 and SGLT-2, restored SP1 and phosphorylated FOXO1 levels, and reduced glucose uptake under high-glucose conditions. FOXO1 overexpression attenuated the BBR-induced reduction in SGLT-2 expression, whereas pharmacological interference with SP1-associated regulation further supported the functional involvement of SP1 in SGLT-2 regulation.
conclusionBBR attenuates diabetic kidney injury, at least in part, through FOXO1/SP1-associated regulation of renal SGLT-2 expression. These findings support the involvement of a FOXO1/SP1-associated regulatory axis in renal tubular glucose handling under diabetic conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.